DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages
Author: Mohamed Mahrous, Medical Writer, Ottawa, Canada. Editor in Chief: A/Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand. April 2017.
We would love your feedback. Fill out our anonymous user survey.
Cysteamine 5% cream (Cysteamine Cream®, ScientisPharma) is a skin-lightening agent used in the treatment of hyperpigmentation disorders such as melasma, postinflammatory hyperpigmentation and lentigines. It has also been used to lighten skin colour overall. It is available as a 50-g tube.
A randomised, double-blind, placebo-controlled clinical trial confirmed the efficacy of cysteamine cream in the treatment of epidermal melasma .
Note: oral cysteamine is used to reduce cystine levels in the treatment of a rare genetic lysosomal storage disorder, nephropathic cystinosis. It is a complex medicine with multiple side effects and risks.
The cream contains cysteamine hydrochloride, a metabolite of L-cysteine and a natural cellular component. L-cysteamine inhibits melanin synthesis. Cysteamine has an unpleasant sulfur odour, but the manufacturers of the cream claim to have reduced this by new technology. Theories how it reduces skin pigment include:
Cysteamine cream should not be used by anyone with a personal or family history of the depigmenting disorder, vitiligo.
No study has been performed during pregnancy or breast-feeding, so it should not be used by pregnant or breast-feeding women.
Cysteamine cream can be applied at any time of year regardless of the intensity of sunlight. It is suitable all skin phototypes.
The cream is applied to the darkened skin of face and neck once daily. It is washed off after 15 minutes using soap and tepid water. After gently drying the skin, a moisturising cream is applied.
To maintain its effects, cysteamine cream should be continued twice weekly indefinitely.
Sunscreens should continue to be used year-round.
Local side effects at the site of application may include:
To date (April 2017), no serious adverse events have been reported.
Books about skin diseases
Note: The New Zealand approved datasheet is the official source of information for this prescription medicine, including approved uses and risk information. Check the New Zealand datasheet on the Medsafe website: http://www.medsafe.govt.nz/
© 2022 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.